GENTICEL : Implementation of a Programmed Trading Mandate

le
0

Genticel (Euronext Paris and Brussels: FR0011790542 - GTCL), a French biotechnology company and leading developer of therapeutic vaccines, today announces that Edmond de Rothschild Investment Partners (EdRIP), a Supervisory Board member, has conferred a programmed trading mandate to an independent investment bank, Oddo Corporate Finance, for EdRIP's funds, shareholders in Genticel.

This programmed trading mandate concerns the divestment of a maximum of 865,427 shares, representing approximately 5.6% of Genticel's shares outstanding as of March 6th, 2015, over a 12-month maximum period beginning on June 4th, 2015. Thi s partial divestment is necessary because certain of EdRIP's funds will reach maturity during the mandate's period. The programmed trading mandate will be implemented in accordance with the terms and conditions, effective as of November 3rd 2010, stipulated in Recommendation n°2010-07 of the Autorité des marchés financiers (France's stock market regulators).

Financial calendar 2015

28 April 2015 Update on 2015 1st Quarter Business & Cash Position
11 June 2015 Annual Shareholders Meeting
28 July 2015 Update on 2015 2nd Quarter Business & Cash Position
21 September 2015 2015 Half-Year Results
28 October 2015 Update on 2015 3rd Quarter Business & Cash Position

Upcoming Genticel meetings with investors

19 March 2015 KBC Securities Healthcare Conference - Brussels, Belgium
21 March 2015 Bolero's Biotech Retail Event, associated with Flandersbio - Leuven, Belgium
25 April 2015 VFB Investor Happening - Brussels, Belgium
27 & 28 April 2015 Small & Midcap Event - Paris

About Genticel
Genticel is a French biopharmaceutical company specialized in the development of therapeutic vaccines aimed at eliminating, at an early stage, the human papillomavirus (HPV) responsible for cervical cancer.

Genticel's most advanced candidate therapeutic vaccine, ProCervix, is currently in a Phase 2 clinical trial. ProCervix is designed to induce the elimination of cervical cells infected with HPV 16 and/or HPV 18. The company has also established Vaxiclase, a technology platform ideally adapted for use in early-intervention immunotherapies against multiple infectious or cancerous diseases. This platform is being used to develop a second therapeutic vaccine candidate, now in its preclinical stage, targeting six of the most pertinent HPV strains in terms of global epidemiology.

Genticel is based in Paris and Toulouse and was awarded 2014 "Prix Biotech d'Avenir" (Most Promising Biotech) in the SW France category of the Deloitte Technology Fast 50 Benchmark.

Since April 4, 2014, Genticel shares have been listed on the regulated Euronext markets in Paris and Brussels.

For more information, please visit Genticel's website, www.genticel.com
 


GENTICEL CONTACT
USA Investor Contact INVESTOR CONTACT PRESS CONTACT
Benedikt Timmerman 
Chief Executive Officer
investors@genticel.com
Brian Stollar
Tel.: +1 (212) 915 2577
bstollar@lifesciadvisors.com
 
Corinne Puissant
Tel.: +33 (0)1 53 67 36 77
cpuissant@actus.fr
 
Alexandra Prisa 
Tel.: +33 (0)1 53 67 36 90
aprisa@actus.fr
 

Information réglementée
Communiqués au titre de l'obligation d'information permanente :
- Autres communiqués
Full and original press release in PDF:
http://www.actusnews.com/documents_communiques/ACTUS-0-39034-150306_Genticel_EdRIP_press_release_VUK_DEF.pdf

Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.

Pour consulter le fichier PDF en intégralité, cliquez ici.

Pour visualiser les documents au format PDF, vous pouvez télécharger gratuitement Acrobat Reader XI.


Valeur associée
  Libellé Bourse Dernier Var. Vol.
Vous devez être membre pour ajouter des commentaires.
Devenez membre, ou connectez-vous.
Aucun commentaire n'est disponible pour l'instant